Carrier screening in preconception consultation in primary care

Journal of Community Genetics

Volumn 3, Issue 3, 2012, Pages 193-203

  Metcalfe, Sylvia A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Carrier screening; Cystic fibrosis; Fragile X syndrome; Haemoglobinopathies; Preconception; Pregnancy; Spinal muscular atrophy; Tay Sachs disease

Indexed keywords

CYSTIC FIBROSIS; DECISION MAKING; FAMILY HISTORY; FRAGILE X SYNDROME; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HEMOGLOBINOPATHY; HETEROZYGOTE; PATIENT ATTITUDE; PERSONAL AUTONOMY; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY; TAY SACHS DISEASE;

EID: 84869122432     PISSN: 1868310X     EISSN: 18686001     Source Type: Journal    
DOI: 10.1007/s12687-011-0071-z     Document Type: Review

References (126)

1. Ahmed S, Green J, Hewison J (2005) Antenatal thalassaemia carrier testing: women's perceptions of "information" and "consent". J Med Screen 12(2):69-77
2. Al Arrayed S, Al Hajeri A (2010) Public awareness of sickle cell disease in Bahrain. Ann Saudi Med 30(4):284-288
3. American College of Obstetricians and Gynecologists (2005) ACOG Committee opinion. Number 325, December 2005. Update on carrier screening for cystic fibrosis. Obstet Gynecol 106(6):1465-1468
4. American College of Obstetricians and Gynecologists (2009) ACOG Committee opinion no. 432: spinal muscular atrophy. Obstet Gynecol 113(5):1194-1196
5. American College of Obstetricians and Gynecologists (2011) ACOG Committee opinion no. 486: update on carrier screening for cystic fibrosis. Obstet Gynecol 117(4):1028-1031
6. Angastiniotis M, Modell B (1998) Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 850:251-269
7. Angastiniotis M, Modell B, Englezos P, Boulyjenkov V (1995) Prevention and control of haemoglobinopathies. Bull World Health Organ 73(3):375-386
8. Anido A, Carlson LM, Taft L, Sherman SL (2005) Women's attitudes toward testing for fragile X carrier status: a qualitative analysis. J Genet Couns 14(4):295-306
9. Anido A, Carlson LM, Sherman SL (2007) Attitudes toward fragile x mutation carrier testing from women identified in a general population survey. J Genet Couns 16(1):97-104
10. Archibald AD, Jaques AM, Wake S, Collins VR, Cohen J, Metcalfe SA (2009) "It's something I need to consider": decisions about carrier screening for fragile X syndrome in a population of nonpregnant women. Am J Med Genet A 149 A (12): 2731-2738
11. Baars MJ, Henneman L, Ten Kate LP (2004) Preconceptional cystic fibrosis carrier screening: opinions of general practitioners, gynecologists, and pediatricians in the Netherlands. Genet Test 8(4):431-436
12. Basel-Vanagaite L, Taub E, Drasinover V, Magal N, Brudner A, Zlotogora J, Shohat M (2008) Genetic carrier screening for spinal muscular atrophy and spinal muscular atrophy with respiratory distress 1 in an isolated population in Israel. Genet Test 12(1):53-56
13. Bekker H, Modell M, Denniss G, Silver A, Mathew C, Bobrow M, Marteau T (1993) Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ 306(6892):1584-1586
14. Bekker H, Denniss G, Modell M, Bobrow M, Marteau T (1994) The impact of population based screening for carriers of cystic fibrosis. J Med Genet 31(5):364-368
15. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF (2011) Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 3(65):65ra64
16. Berkenstadt M, Ries-Levavi L, Cuckle H, Peleg L, Barkai G (2007) Preconceptional and prenatal screening for fragile X syndrome: experience with 40, 000 tests. Prenat Diagn 27(11):991-994
17. Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Tambor ES, Holtzman NA (1996) Educating patients about cystic fibrosis carrier screening in a primary care setting. Arch Fam Med 5(6):336-340
18. Borry P, Henneman L, Lakeman P, Ten Kate LP, Cornel MC, Howard HC (2011) Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod 26(5):972-977
19. Botkin JR, Alemagno S (1992) Carrier screening for cystic fibrosis: a pilot study of the attitudes of pregnant women. Am J Public Health 82(5):723-725
20. Boulton M, Cummings C, Williamson R (1996) The views of general practitioners on community carrier screening for cystic fibrosis. Br J Gen Pract 46(406):299-301
21. Cao A, Rosatelli MC, Monni G, Galanello R (2002) Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 29(2):305-328, vi-vii
22. Chen LS, Goodson P (2007) Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: a theory-guided systematic review. Genet Med 9(7):442-450
23. Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW 3rd, Phillips JA 3rd (1996) Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet 58(3):617-627
24. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB (2010) Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 18(10):1077-1083
25. Cronister A, Di Maio M, Mahoney MJ, Donnenfeld AE, Hallam S (2005) Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet Med 7(4):246-250
26. Cuckle H, Quirke P, Sehmi I, Lewis F, Murray J, Cross D, Cuckle P, Ozols B (1996) Antenatal screening for cystic fibrosis. Br J Obstet Gynaecol 103(8):795-799
27. Decruyenaere M, Evers-Kiebooms G, Denayer L, Van Den Berghe H (1992) Cystic fibrosis: community knowledge and attitudes towards carrier screening and prenatal diagnosis. Clin Genet 41(4):189-196
28. Delatycki MB (2008) Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res Hum Genet 11(4):422-430
29. Dodge JA, Lewis PA, Stanton M, Wilsher J (2007) Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 29(3):522-526
30. Faden RR, Tambor ES, Chase GA, Geller G, Hofman KJ, Holtzman NA (1994) Attitudes of physicians and genetics professionals toward cystic fibrosis carrier screening. Am J Med Genet 50(1):1-11
31. Fanos JH, Spangner KA, Musci TJ (2006) Attitudes toward prenatal screening and testing for Fragile X. Genet Med 8(2):129-133
32. Finucane B (1996) Should all pregnant women be offered carrier testing for fragile X syndrome? Clin Obstet Gynecol 39(4):772-782
33. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG Jr, Warren ST et al (1991) Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67(6):1047-1058
34. Gason AA, Sheffield E, Bankier A, Aitken MA, Metcalfe S, Barlow Stewart K, Delatycki MB (2003) Evaluation of a Tay-Sachs disease screening program. Clin Genet 63(5):386-392
35. Geva E, Yaron Y, Shomrat R, Ben-Yehuda A, Zabari S, Peretz H, Naiman T, Yeger H, Orr-Urtreger A (2000) The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families. Genet Test 4(3):289-292
36. Godard B, Ten Kate L, Evers-Kiebooms G, Ayme S (2003) Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 11(Suppl 2):S49-S87
37. Gordon C, Walpole I, Zubrick SR, Bower C (2003) Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later. Am J Med Genet 120 A (2): 199-208
38. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ, Subcommittee on Cystic Fibrosis Screening AoGS-CAACoMG (2001) Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 3(2):149-154
39. Gross SJ, Pletcher BA, Monaghan KG, Professional Practice Guidelines Committee (2008) Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 10(1):54-56
40. Hagerman RJ, Hagerman PJ (2002) Fragile X syndrome: diagnosis, treatment, and research. Johns Hopkins University Press
41. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57(1):127-130
42. Hantash FM, Goos DM, Crossley B, Anderson B, Zhang K, Sun W, Strom CM (2011) FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med 13(1):39-45
43. Harris HJ, Scotcher D, Craufurd D, Wallace A, Harris R (1992) Cystic fibrosis carrier screening at first diagnosis of pregnancy in general practice. Lancet 339(8808):1539
44. Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R (1993) Cystic fibrosis carrier testing in early pregnancy by general practitioners. BMJ 306(6892):1580-1583
45. Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R (1996) Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice. Br J Gen Pract 46(405):225-227
46. Hartley NE, Scotcher D, Harris H, Williamson P, Wallace A, Craufurd D, Harris R (1997) The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 34(6):459-464
47. Henneman L, Bramsen I, Van Os TA, Reuling IE, Heyerman HG, Van Der Laag J, Van Der Ploeg HM, Ten Kate LP (2001a) Attitudes towards reproductive issues and carrier testing among adult patients and parents of children with cystic fibrosis (CF). Prenat Diagn 21(1):1-9
48. Henneman L, Bramsen I, Van Der Ploeg HM, Ader HJ, Van Der Horst HE, Gille JJ, Ten Kate LP (2001b) Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet 38(10):695-703
49. Henneman L, Bramsen I, Van Der Ploeg HM, Ten Kate LP (2002) Preconception cystic fibrosis carrier couple screening: impact, understanding, and satisfaction. Genet Test 6(3):195-202
50. Henneman L, Bramsen I, Van Kempen L, Van Acker MB, Pals G, Van Der Horst HE, Ader HJ, Van Der Ploeg HM, Ten Kate LP (2003) Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. Comm Genet 6(1):5-13
51. Heredero-Baute L (2004) Community-based program for the diagnosis and prevention of genetic disorders in Cuba. Publ Health Genomics 7(2-3):130-136
52. Hill MK, Archibald AD, Cohen J, Metcalfe SA (2010) A systematic review of population screening for fragile X syndrome. Genet Med 12(7):396-410
53. Honnor M, Zubrick SR, Walpole I, Bower C, Goldblatt J (2000) Population screening for cystic fibrosis in Western Australia: community response. Am J Med Genet 93(3):198-204
54. Huang KF, Chen WY, Tsai YC, Lin CC, Chen SH, Tseng CY, Tzeng CC (2003) Original article pilot screening for fragile X carrier in pregnant women of southern Taiwan. J Chin Med Assoc 66(4):204-209
55. Human Genetics Society of Australasia (2010) Cystic fibrosis population screening position paper
56. Ioannou L, Massie J, Collins V, McClaren B, Delatycki MB (2010) Population-based genetic screening for cystic fibrosis: attitudes and outcomes. Publ Health Genomics 13(7-8):449-456
57. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, Greco C, Des Portes V, Jardini T, Levine R, Berry-Kravis E, Brown WT, Schaeffer S, Kissel J, Tassone F, Hagerman PJ (2003) Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 72(4):869-878
58. Kaback MM (2001) Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet 44:253-265
59. Kallinen J, Marin K, Heinonen S, Mannermaa A, Palotie A, Ryynanen M (2001) Wide scope prenatal diagnosis at Kuopio University Hospital 1997-1998: integration of gene tests and fetal karyotyping. BJOG 108(5):505-509
60. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922):1073-1080
61. Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP (2009) Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation? Eur J Hum Genet 17(8):999-1009
62. Levenkron JC, Loader S, Rowley PT (1997) Carrier screening for cystic fibrosis: test acceptance and one year follow-up. Am J Med Genet 73(4):378-386
63. Lévesque S, Dombrowski C, Morel ML, Rehel R, Côté JS, Bussières J, Morgan K, Rousseau F (2009) Screening and instability of FMR1 alleles in a prospective sample of 24, 449 mother-newborn pairs from the general population. Clin Genet 76(6):511-523
64. Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr, Rowley PT (1996) Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 59(1):234-247
65. Locock L, Kai J (2008) Parents' experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era. Br J Gen Pract 58(548):161-168
66. Massie J, Petrou V, Forbes R, Curnow L, Ioannou L, Du Sart D, Bankier A, Delatycki M (2009) Population-based carrier screening for cystic fibrosis in Victoria: the first three years experience. Aust N Z J Obstet Gynaecol 49(5):484-489
67. Maxwell SJ, Kyne G, Molster C, Barker NM, Ormsby J, O'Leary P (2011) Perceptions of population cystic fibrosis prenatal and preconception carrier screening among individuals with cystic fibrosis and their family members. Genet Test Mol Biomarkers 15(3):159-164
68. McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M (2008) 'It is not in my world': an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 16(4):435-444
69. McClaren BJ, Metcalfe S, Aitken M, Massie J, Ukoumunne OC, Amor DJ (2010) Uptake of cystic fibrosis carrier testing in families after diagnosis through newborn screening. Eur J Hum Genet 18(10):1084-1089
70. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ (2005) Genetic counseling for fragile X syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 14(4):249-270
71. McConkie-Rosell A, Abrams L, Finucane B, Cronister A, Gane LW, Coffey SM, Sherman S, Nelson LM, Berry-Kravis E, Hessl D, Chiu S, Street N, Vatave A, Hagerman RJ (2007) Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Couns 16(5):593-606
72. Meadows KL, Sherman SL (1996) Fragile X syndrome: examination of issues pertaining to population-based screening. Screening 4:175-192
73. Melancon MJ, De Braekeleer M (1996) Adolescents' attitude towards carrier testing for cystic fibrosis. Eur J Hum Genet 4(6):305-306
74. Mennie M, Campbell H, Liston WA, Brock DJ (1998) Attitudes of general practitioners to screening for cystic fibrosis. J Med Screen 5(1):11-15
75. Metcalfe S, Hurworth R, Newstead J, Robins R (2002) Needs assessment study of genetics education for general practitioners in Australia. Genet Med 4(2):71-77
76. Metcalfe S, Jacques A, Archibald A, Burgess T, Collins V, Henry A, McNamee K, Sheffield L, Slater H, Wake S, Cohen J (2008) A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genet Med 10(7):525-535
77. Mitchell JJ, Capua A, Clow C, Scriver CR (1996) Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 59(4):793-798
78. Modell M (1993) Screening for carriers of cystic fibrosis-a general practitioner's perspective. BMJ 307(6908):849-852
79. Modell M, Wonke B, Anionwu E, Khan M, Tai SS, Lloyd M, Modell B (1998) A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders. BMJ 317(7161):788-791
80. Muralidharan K, Wilson RB, Ogino S, Nagan N, Curtis C, Schrijver I (2011) Population carrier screening for spinal muscular atrophy a position statement of the association for molecular pathology. J Mol Diagn 13(1):3-6
81. Musci TJ (2005) Screening for single gene genetic disease. Gynecol Obstet Invest 60(1):19-26
82. Musci TJ, Caughey AB (2005) Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 192(6):1905-1912
83. Myers MF, Bernhardt BA, Tambor ES, Holtzman NA (1994) Involving consumers in the development of an educational program for cystic fibrosis carrier screening. Am J Hum Genet 54(4):719-726
84. NHS. Thalassaemia and Sickle Cell Screening Programme. Accessed July 2011, from http://sct.screening.nhs.uk/index.php
85. Nolin SL, Lewis FA 3rd, Ye LL, Houck GE Jr, Glicksman AE, Limprasert P, Li SY, Zhong N, Ashley AE, Feingold E, Sherman SL, Brown WT (1996) Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 59(6):1252-1261
86. Nolin SL, Brown WT, Glicksman A, Houck GE Jr, Gargano AD, Sullivan A, Biancalana V, Brondum-Nielsen K, Hjalgrim H, Holinski-Feder E, Kooy F, Longshore J, Macpherson J, Mandel JL, Matthijs G, Rousseau F, Steinbach P, Vaisanen ML, Von Koskull H, Sherman SL (2003) Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 72(2):454-464
87. Ormond KE, Iris M, Banuvar S, Minogue J, Annas GJ, Elias S (2007) What do patients prefer: informed consent models for genetic carrier testing. J Genet Couns 16(4):539-550
88. O'Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373(9678):1891-1904
89. Otsuka S, Sakamoto Y, Siomi H, Itakura M, Yamamoto K, Matumoto H, Sasaki T, Kato N, Nanba E (2010) Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain Dev 32(2):110-114
90. Palomaki GE (1994) Population based prenatal screening for the fragile X syndrome. J Med Screen 1(1):65-72
91. Payne Y, Williams M, Cheadle J, Stott NC, Rowlands M, Shickle D, West G, Meredith L, Goodchild M, Harper PS, Clarke A (1997) Carrier screening for cystic fibrosis in primary care: evaluation of a project in South Wales. The South Wales Cystic Fibrosis Carrier Screening Research Team. Clin Genet 51(3):153-163
92. Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, Barkai G (2000) Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 20(8):611-614
93. Poppelaars FA, Van Der Wal G, Braspenning JC, Cornel MC, Henneman L, Langendam MW, Ten Kate LP (2003a) Possibilities and barriers in the implementation of a preconceptional screening programme for cystic fibrosis carriers: a focus group study. Public Health 117(6):396-403
94. Poppelaars FA, Henneman L, Ader HJ, Cornel MC, Hermens RP, Van Der Wal G, Ten Kate LP (2003b) How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population. Comm Genet 6(3):157-165
95. Poppelaars FA, Henneman L, Ader HJ, Cornel MC, Hermens RP, Van Der Wal G, Ten Kate LP (2004a) Preconceptional cystic fibrosis carrier screening: attitudes and intentions of the target population. Genet Test 8(2):80-89
96. Poppelaars FA, Ader HJ, Cornel MC, Henneman L, Hermens RP, Van Der Wal G, Ten Kate LP (2004b) Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening. J Genet Couns 13(1):31-44
97. Prior TW (2010) Spinal muscular atrophy: a time for screening. Curr Opin Pediatr 22(6):696-702
98. Prior TW, Professional Practice Guidelines Committee (2008) Carrier screening for spinal muscular atrophy. Genet Med 10(11):840-842
99. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, Conlan T, Schmalz B, Montgomery L, Ziegler K, Noonan C, Hashimoto S, Garner S (2010) Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 152 A (7): 1608-1616
100. Qureshi N, Armstrong S, Modell B (2006) GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. Fam Pract 23(1):106-110
101. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066-1073
102. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N et al (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245(4922):1059-1065
103. Ryynanen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K (1999) Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 7(2):212-216
104. Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R (2010) Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat 31(11):1240-1250
105. Sherman S, Pletcher BA, Driscoll DA (2005) Fragile X syndrome: diagnostic and carrier testing. Genet Med 7(8):584-587
106. Snow K, Doud LK, Hagerman R, Pergolizzi RG, Erster SH, Thibodeau SN (1993) Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet 53(6):1217-1228
107. Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A (2003) Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 7(16):1-106
108. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, Castellani C (2007) A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6(1):57-65
109. Southern KW, Merelle MM, Dankert-Roelse JE, Nagelkerke AD (2009) Newborn screening for cystic fibrosis. Cochrane Database Syst Rev (1): CD001402. doi:10.1002/14651858. CD001402.pub2
110. Spence WC, Black SH, Fallon L, Maddalena A, Cummings E, Menapace-Drew G, Bick DP, Levinson G, Schulman JD, Howard-Peebles PN (1996) Molecular fragile X screening in normal populations. Am J Med Genet 64(1):181-183
111. Srinivasan BS, Evans EA, Flannick J, Patterson AS, Chang CC, Pham T, Young S, Kaushal A, Lee J, Jacobson JL, Patrizio P (2010) A universal carrier test for the long tail of Mendelian disease. Reprod Biomed online 21(4):537-551
112. Strom CM, Crossley B, Buller-Buerkle A, Jarvis M, Quan F, Peng M, Muralidharan K, Pratt V, Redman JB, Sun W (2011) Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis. Genet Med 13(2):166-172
113. Su YN, Hung CC, Lin SY, Chen FY, Chern JP, Tsai C, Chang TS, Yang CC, Li H, Ho HN, Lee CN (2011) Carrier screening for spinal muscular atrophy (SMA) in 107, 611 pregnant women during the period 2005-2009: a prospective population-based cohort study. PLoS One 6(2):e17067
114. Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Holtzman NA (1994) Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 55(4):626-637
115. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, Davidov B, Ehrlich S, Drasinover V, Taub E, Halpern GJ, Ginott N, Shohat M (2001) Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 69(2):351-360
116. Watson EK, Williamson R, Chapple J (1991a) Attitudes to carrier screening for cystic fibrosis: a survey of health care professionals, relatives of sufferers and other members of the public. Br J Gen Pract 41(347):237-240
117. Watson EK, Mayall E, Chapple J, Dalziel M, Harrington K, Williams C, Williamson R (1991b) Screening for carriers of cystic fibrosis through primary health care services. BMJ 303(6801):504-507
118. Weinreich SS, De Lange-De Klerk ES, Rijmen F, Cornel MC, De Kinderen M, Plass AM (2009) Raising awareness of carrier testing for hereditary haemoglobinopathies in high-risk ethnic groups in the Netherlands: a pilot study among the general public and primary care providers. BMC Public Health 9:338
119. Welkenhuysen M, Evers-Kiebooms G, Decruyenaere M, Van Den Berghe H, Bande-Knops J, Van Gerven V (1996) Adolescents' attitude towards carrier testing for cystic fibrosis and its relative stability over time. Eur J Hum Genet 4(1):52-62
120. WHO (2006) Thalassaemia and other haemoglobinopathies: report by the Secretariat
121. Wildhagen MF, Van Os TA, Polder JJ, Ten Kate LP, Habbema JD (1998) Explorative study of costs, effects and savings of screening for female fragile X premutation and full mutation carriers in the general population. Comm Genet 1(1):36-47
122. Wilfond BS, Fost N (1990) The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA 263(10):2777-2783
123. Williamson R (1993) Universal community carrier screening for cystic fibrosis? Nat Genet 3(3):195-201
124. Wong L, George E, Tan J-A (2011a) A holistic approach to education programs in thalassemia for a multi-ethnic population: consideration of perspectives, attitudes, and perceived needs. J Comm Genet 2(2):71-79
125. Wong LP, George E, Tan JA (2011b) Public perceptions and attitudes toward thalassaemia: influencing factors in a multi-racial population. BMC Public Health 11:193
126. Zlotogora J, Carmi R, Lev B, Shalev SA (2009) A targeted population carrier screening program for severe and frequent genetic diseases in Israel. Eur J Hum Genet 17(5):591-597